Stock Ideas
Stocks
Funds
Screener
Sectors
Watchlists
SNPX

SNPX - Synaptogenix, Inc. Stock Price, Fair Value and News

4.43USD-0.08 (-1.77%)Delayed

Market Summary

SNPX
USD4.43-0.08
Delayed
-1.77%

SNPX Stock Price

View Fullscreen

SNPX RSI Chart

SNPX Valuation

Market Cap

5.5M

Price/Earnings (Trailing)

-1.21

Price/Sales (Trailing)

3.18

EV/EBITDA

4.6

Price/Free Cashflow

-1.03

SNPX Price/Sales (Trailing)

SNPX Profitability

EBT Margin

-264.19%

Return on Equity

-20.56%

Return on Assets

-15.42%

Free Cashflow Yield

-97.23%

SNPX Fundamentals

SNPX Revenue

Revenue (TTM)

1.7M

Rev. Growth (Yr)

89.68%

Rev. Growth (Qtr)

-49.92%

SNPX Earnings

Earnings (TTM)

-4.5M

Earnings Growth (Yr)

87.92%

Earnings Growth (Qtr)

79.25%

Breaking Down SNPX Revenue

Last 7 days

8.3%

Last 30 days

-3.9%

Last 90 days

-4.7%

Trailing 12 Months

-81.7%

How does SNPX drawdown profile look like?

SNPX Financial Health

Current Ratio

4.58

SNPX Investor Care

Shares Dilution (1Y)

318.90%

Diluted EPS (TTM)

-27.36

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20241.7M000
2023726.8K1.1M1.5M1.6M
202230.6K54.1K192.3K335.0K
20210104.5K55.8K7.1K
2020322.3K266.0K209.6K153.2K
2019000378.7K

Tracking the Latest Insider Buys and Sells of Synaptogenix, Inc.

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Dec 16, 2022
alkon daniel l.
sold
-23,072
1.1719
-19,688
president and cso
Dec 16, 2022
bernstein bruce
sold
-26,367
1.1719
-22,500
-
Dec 16, 2022
schechter jonathan
sold
-23,731
1.1719
-20,250
-
Dec 16, 2022
singer william s.
sold
-31,641
1.1719
-27,000
-
Dec 16, 2022
silverman joshua
sold
-22,280
1.1719
-19,012
-
Dec 16, 2022
tuchman alan j
sold
-31,641
1.1719
-27,000
chief executive officer
Dec 16, 2022
weinstein robert
sold
-31,641
1.1719
-27,000
chief financial officer
Jul 13, 2021
perry george
acquired
-
-
40,000
-
Jul 13, 2021
alkon daniel l.
acquired
-
-
43,750
president and cso
Jul 13, 2021
silverman joshua
acquired
-
-
42,250
-

1–10 of 19

Which funds bought or sold SNPX recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
May 20, 2024
Virtu Financial LLC
sold off
-100
-8,000
-
-%
May 15, 2024
CITADEL ADVISORS LLC
new
-
15,665
15,665
-%
May 15, 2024
STATE STREET CORP
unchanged
-
-1,696
3,769
-%
May 15, 2024
MORGAN STANLEY
unchanged
-
-193
429
-%
May 15, 2024
FIRST MANHATTAN CO. LLC.
sold off
-100
-6.00
-
-%
May 15, 2024
Tower Research Capital LLC (TRC)
reduced
-73.58
-86.00
19.00
-%
May 15, 2024
TWO SIGMA ADVISERS, LP
sold off
-100
-12,507
-
-%
May 15, 2024
TWO SIGMA SECURITIES, LLC
new
-
15,639
15,639
-%
May 15, 2024
MILLENNIUM MANAGEMENT LLC
sold off
-100
-10,604
-
-%
May 15, 2024
Royal Bank of Canada
unchanged
-
-
-
-%

1–10 of 30

Are Funds Buying or Selling SNPX?

Are funds buying SNPX calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own SNPX
No. of Funds

Unveiling Synaptogenix, Inc.'s Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 06, 2024
intracoastal capital, llc
4.99%
1,048,214
SC 13G/A
Feb 08, 2023
intracoastal capital, llc
9.99%
786,710
SC 13G/A
Jan 18, 2023
haywood george weaver
0%
0
SC 13G/A
Feb 11, 2022
intracoastal capital, llc
9.99%
740,339
SC 13G/A

Recent SEC filings of Synaptogenix, Inc.

View All Filings
Date Filed Form Type Document
Jun 21, 2024
8-K
Current Report
May 15, 2024
10-Q
Quarterly Report
Apr 10, 2024
4
Insider Trading
Apr 10, 2024
4
Insider Trading
Apr 10, 2024
4
Insider Trading
Apr 10, 2024
4
Insider Trading

Peers (Alternatives to Synaptogenix, Inc.)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
46.6B
6.8B
-13.25% 0.10%
-7.8
6.8
-64.45% -224.75%
32.4B
2.0B
59.65% 29.92%
-97.58
16.18
75.20% 68.82%
22.5B
216.3K
-0.77% 465779.94%
-2.5K
104.0K
- -8.13%
16.1B
2.5B
1.33% -1.46%
78.18
6.5
13.74% 186.89%
14.4B
3.8B
3.45% 4.03%
19.35
3.83
8.58% 129.81%
MID-CAP
5.2B
107.9M
- 52.91%
-9.53
48.09
54.84% -28.31%
4.9B
524.1M
-4.71% -52.64%
-11.63
9.26
394.93% 39.61%
3.9B
251.0M
12.43% 12.43%
-13.27
15.67
73.58% -86.73%
3.6B
240.7M
11.69% -16.59%
-7.58
12.77
-1.03% -213.92%
3.0B
813.8M
21.06% -43.91%
-1.7K
3.66
56.43% 98.83%
2.1B
996.6M
5.00% 74.19%
-5.32
2.13
-26.66% 65.49%
SMALL-CAP
2.0B
411.3M
11.22% 30.25%
30.38
4.81
60.38% -34.49%
632.3M
881.7K
18.10% 671.45%
-18.73
481.06
-77.61% 33.36%
286.3M
4.2M
21.56% 73.74%
-2.29
68.83
-66.30% 48.24%
19.8M
2.1M
-10.16% -79.46%
-0.86
7.61
-13.45% 69.54%

Synaptogenix, Inc. News

Latest updates
Defense World12 Jul 202402:00 pm
Defense World09 Jul 202407:17 am

Synaptogenix, Inc. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
Income Statement (Quarterly)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22020Q42020Q32020Q22020Q12019Q42019Q3
Revenue68.2%463,395275,439549,995427,159396,357145,212140,73044,4874,6102,5182,4453,8965,3466,79775,64170,86780,51390,159
Operating Expenses-20.7%1,691,4942,132,4081,429,7921,829,7132,921,9415,888,8673,167,2063,796,3913,282,5324,238,5632,929,3782,295,1733,179,7072,576,4062,576,4062,608,211-3,914,722
  S&GA Expenses-30.4%1,082,2451,554,5151,217,6891,522,5022,044,2244,475,8081,682,5121,855,2901,796,4582,876,9252,092,6621,308,8931,766,3771,778,1872,013,0892,214,966-2,131,205
  R&D Expenses5.4%609,249577,893212,103307,211877,7171,413,0591,484,6941,941,1011,486,0741,361,638836,716986,2801,607,294410,292563,317393,245-845,797
EBITDA Margin27.9%-2.64-3.66-0.36-3.91-5.51-16.62-74.28-262-416-1,773-191-114------
Income Taxes-------------------
Earnings Before Taxes79.2%-206,699-995,969763,203-4,093,954-1,711,7844,482,345-3,026,476-3,751,904-3,277,922-4,236,045-2,926,933-2,293,842-2,295,376-4,269,609-4,269,609-2,537,344--3,824,563
EBT Margin27.9%-2.64-3.66-0.37-3.92-5.51-16.64-74.31-262-416-1,773-191-114------
Net Income79.2%-206,699-995,969763,203-4,093,954-1,711,7844,482,345-3,026,476-3,751,904-3,277,922-4,236,045-2,926,933-2,293,842--4,269,609-4,269,609-2,537,344--3,824,563
Net Income Margin27.9%-2.64-3.66-0.37-3.92-5.51-16.64-74.31-262-416-1,773-227-121------
Free Cashflow-71.8%-1,831,541-1,066,000-1,171,910-1,240,156-1,697,850-2,785,657-2,420,484-2,524,083-3,485,406-2,045,166-1,080,236-1,998,606------
Balance Sheet
(In Thousands)
Balance Sheet
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32019Q4
Assets-5.5%29,39931,11432,36033,43736,52938,60827,35129,57932,35335,52532,35932,96016,3476,75129,15017,898
  Current Assets-5.6%28,82830,53332,34133,41636,50738,58627,32929,55832,33435,50432,34032,94016,3266,72929,12617,876
    Cash Equivalents-8.2%26,30028,66131,70032,90035,78137,47826,33428,7552,86334,21431,29531,70214,8485,79527,00017,382
  Net PPE-7.6%17.0019.0020.0021.0022.0022.0022.0021.0019.0020.0018.0020.0021.0022.0023.0022.00
Liabilities18.0%6,5235,5293,9326,5302,3433,193---1,995------
  Current Liabilities47.3%6,3004,2761,8182,7731,2771,3136846266691,9951,0077709371,6121,300479
Shareholder's Equity-9.4%22,05324,34726,74124,83031,46432,69326,66728,95331,68433,53031,35132,19015,4095,139-17,419
  Retained Earnings-1.3%-34,035-33,610-32,381-32,019-21,809-19,831-24,197-21,171-17,419-14,141-9,905-6,978-4,684-1,530--
  Additional Paid-In Capital-3.2%56,08957,95759,12056,84953,27352,52450,86450,12449,10347,67141,25639,16820,0936,669--
Shares Outstanding12.6%1,085963700295300291280278278269177142119---
Float----6,624---35,194---59,482----
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q3
Cashflow From Operations-71.8%-1,831-1,066-1,171-1,239-1,695-2,783-2,418-2,524-3,485-2,045-1,080-1,998-3,586-1,205-3,251-1,906-1,738--
Cashflow From Investing75.0%-500-2,000--669*-2.04-2.14-2.25---------2.81-2.60--
Cashflow From Financing100.0%--51*49*--13,930--5534,96867318,85212,640-19,999--16,520--
Get Full Access to Grufity – and Unlimited Downloads
Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.
Try For Just $1.99

SNPX Income Statement

2024-03-31
Condensed Statements of Comprehensive Loss - USD ($)
3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
OPERATING EXPENSES:  
Research and development$ 609,249$ 877,717
General and administrative1,082,2452,044,224
TOTAL OPERATING EXPENSES1,691,4942,921,941
OTHER INCOME:  
Interest income463,395396,357
Share of net loss in equity investment(8,600) 
Change in fair value of warrant liability58,000588,000
Change in fair value of derivative liability972,000225,800
TOTAL OTHER INCOME1,484,7951,210,157
Net loss before income taxes(206,699)(1,711,784)
Net loss(206,699)(1,711,784)
Preferred Stock dividends218,459266,074
Net Loss attributable to common stockholders(425,158)(1,977,858)
Change in fair value of available for sale debt security(700) 
Net comprehensive loss$ (425,858)$ (1,977,858)
PER SHARE DATA:  
Basic loss per common share (in dollars per share)[1]$ (0.41)$ (6.59)
Diluted loss per common share (in dollars per share)[1]$ (0.41)$ (6.59)
Basic weighted average common shares outstanding (in shares)[1]1,036,700300,100
Diluted weighted average common shares outstanding (in shares)[1]1,036,700300,100
[1]Adjusted to reflect the impact of the 1:25 reverse stock split that became effective on April 4, 2024.

SNPX Balance Sheet

2024-03-31
Condensed Balance Sheets - USD ($)
Mar. 31, 2024
Dec. 31, 2023
CURRENT ASSETS  
Cash and cash equivalents$ 26,329,957$ 28,661,498
Prepaid Clinical trial expenses 375,085
Available for sale debt security1,937,8001,438,500
Prepaid expenses and other current assets560,58357,677
TOTAL CURRENT ASSETS28,828,34030,532,760
Equity method investment553,802562,402
Fixed assets, net of accumulated depreciation17,10618,505
TOTAL ASSETS29,399,24831,113,667
CURRENT LIABILITIES  
Accounts payable238,905444,633
Accrued expenses45,692435,891
Accrued Series B Convertible Preferred payments payable6,015,1153,395,945
TOTAL CURRENT LIABILITIES6,299,7124,276,469
Warrant liability82,000140,000
Derivative liability141,0001,113,000
TOTAL LIABILITIES6,522,7125,529,469
Commitments and contingencies
Series B Convertible redeemable preferred stock, $.0001 par value and $1,000 face value, 1,000,000 shares authorized; 3,000 and 6,000 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively.Liquidation preference of $3,000,000 plus dividends accrued at 7% per annum of $839,228 as of March 31, 2024.823,5551,236,940
STOCKHOLDERS' EQUITY  
Common stock - 150,000,000 shares authorized, $0.0001 par value;1,085,237 shares issued and outstanding as of March 31, 2024 and963,489 shares issued and outstanding as of December 31, 2023.[1]10996
Additional paid-in capital56,088,57657,957,008
Accumulated other comprehensive income202902
Accumulated deficit(34,035,906)(33,610,748)
TOTAL STOCKHOLDERS' EQUITY22,052,98124,347,258
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY$ 29,399,248$ 31,113,667
[1]Adjusted to reflect the impact of the 1:25 reverse stock split that became effective on April 4, 2024.
SNPX
Synaptogenix, Inc. operates as a biopharmaceutical company with product candidates in pre-clinical and clinical development. The company focuses on developing a product platform based upon a drug candidate called Bryostatin-1 for the treatment of Alzheimer's disease. It is also evaluating therapeutic applications of bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as fragile X syndrome, multiple sclerosis, and Niemann-pick type C disease. The company was incorporated in 2012 and is headquartered in New York, New York.
 CEO
 WEBSITEsynaptogen.com
 INDUSTRYBiotechnology
 EMPLOYEES5

Synaptogenix, Inc. Frequently Asked Questions


What is the ticker symbol for Synaptogenix, Inc.? What does SNPX stand for in stocks?

SNPX is the stock ticker symbol of Synaptogenix, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Synaptogenix, Inc. (SNPX)?

As of Mon Jul 15 2024, market cap of Synaptogenix, Inc. is 5.46 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of SNPX stock?

You can check SNPX's fair value in chart for subscribers.

What is the fair value of SNPX stock?

You can check SNPX's fair value in chart for subscribers. The fair value of Synaptogenix, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Synaptogenix, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for SNPX so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Synaptogenix, Inc. a good stock to buy?

The fair value guage provides a quick view whether SNPX is over valued or under valued. Whether Synaptogenix, Inc. is cheap or expensive depends on the assumptions which impact Synaptogenix, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for SNPX.

What is Synaptogenix, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Mon Jul 15 2024, SNPX's PE ratio (Price to Earnings) is -1.21 and Price to Sales (PS) ratio is 3.18. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. SNPX PE ratio will change depending on the future growth rate expectations of investors.